Beyond Air Licenses Commercial Rights To Selective Neuronal Nitric Oxide Synthase Inhibitors For The Treatment Of Autism Spectrum Disorder From Hebrew University Of Jerusalem
Portfolio Pulse from Benzinga Newsdesk
Beyond Air has licensed commercial rights for neuronal nitric oxide synthase (nNOS) inhibitors for autism spectrum disorder (ASD) treatment from Hebrew University of Jerusalem. The preclinical results show a reversal of ASD phenotypes, and a first-in-human clinical trial is planned for 2025.
June 15, 2023 | 8:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Beyond Air has licensed commercial rights for nNOS inhibitors for ASD treatment from Hebrew University, with a first-in-human clinical trial planned for 2025.
Beyond Air's licensing of commercial rights for nNOS inhibitors for ASD treatment from Hebrew University is a significant development for the company. The preclinical results show a reversal of ASD phenotypes, and if the first-in-human clinical trial planned for 2025 is successful, it could lead to a new treatment option for ASD. This news is likely to have a positive short-term impact on Beyond Air's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100